Edith Cowan University

Research Online
Research outputs 2014 to 2021
1-1-2019

Associations between habitual flavonoid intake and hospital
admissions for atherosclerotic cardiovascular disease: A
prospective cohort study
Frederik Dalgaard
Nicola P. Bondonno
Edith Cowan University

Kevin Murray
Catherine P. Bondonno
Edith Cowan University

Joshua R. Lewis
Edith Cowan University

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013
Part of the Medicine and Health Sciences Commons
10.1016/S2542-5196(19)30212-8
Dalgaard, F., Bondonno, N. P., Murray, K., Bondonno, C. P., Lewis, J. R., Croft, K. D., ... Hodgson, J. M. (2019).
Associations between habitual flavonoid intake and hospital admissions for atherosclerotic cardiovascular
disease: A prospective cohort study. The Lancet Planetary Health, 3(11), 450-459. Available here
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/7200

Authors
Frederik Dalgaard, Nicola P. Bondonno, Kevin Murray, Catherine P. Bondonno, Joshua R. Lewis, Kevin D.
Croft, Cecilie Kyrø, Gunnar Gislason, Augustin Scalbert, Aedin Cassidy, Anne Tjønneland, Kim Overvad, and
Jonathan M. Hodgson

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/7200

Articles

Associations between habitual flavonoid intake and hospital
admissions for atherosclerotic cardiovascular disease:
a prospective cohort study
Frederik Dalgaard*, Nicola P Bondonno*, Kevin Murray, Catherine P Bondonno, Joshua R Lewis, Kevin D Croft, Cecilie Kyrø, Gunnar Gislason,
Augustin Scalbert, Aedin Cassidy, Anne Tjønneland, Kim Overvad, Jonathan M Hodgson

Summary

Background Flavonoids, compounds found in plant-based foods and beverages, might ameliorate vascular damage
and atherosclerosis. Therefore, our aim was to assess the association between flavonoid intake and hospital admissions
due to atherosclerotic cardiovascular disease.
Methods In this prospective cohort study, participants from the Danish Diet, Cancer, and Health Study were crosslinked with Danish nationwide registries. Eligible participants were aged 50–65 years, had no previous history of
atherosclerotic cardiovascular disease, and had completed a food-frequency questionnaire at baseline. We examined
associations between flavonoid intake (calculated from food-frequency questionnaires with use of the Phenol-Explorer
database) and hospital admissions for atherosclerotic cardiovascular disease, ischaemic heart disease, ischaemic
stroke, or peripheral arterial disease. We obtained hazard ratios (HRs) using restricted cubic splines based on Cox
proportional hazards models.
Findings Of the participants recruited to the Danish Diet, Cancer, and Health study between 1993 and 1997, our study
population was comprised of 53 552 participants, with a median follow-up of 21 years (IQR 15–22). During follow-up,
8773 participants were admitted to hospital for atherosclerotic cardiovascular disease. We observed non-linear
associations between flavonoid intake and hospital admissions, plateauing at total flavonoid intakes of approximately
1000 mg per day. Compared with an intake of 175 mg per day, an intake of 1000 mg per day was associated with a 14%
lower risk of atherosclerotic cardiovascular disease (HR 0·86, 95% CI 0·81–0·91). For disease subtypes, we observed
a 9% lower risk of ischaemic heart disease (0·91, 0·85–0·98), a non-significant 9% lower risk of ischaemic stroke
(0·91, 0·82–1·01), and a 32% lower risk of peripheral artery disease (0·68, 0·60–0·78). The overall associations were
stronger in smokers than in non-smokers, as well as stronger in consumers of high (>20 g per day) quantities of
alcohol than in those consuming low-to-moderate (≤20 g per day) quantities.
Interpretation Our results suggest that ensuring an adequate consumption of flavonoid-rich foods, particularly in
subpopulations at risk of atherosclerosis such as smokers and consumers of high quantities of alcohol might mitigate
some of the risk of atherosclerotic cardiovascular disease. More studies are needed to support and validate these data.
Funding Danish Cancer Society.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
The exploration of evidence-based approaches to prevent
cardiovascular disease is crucial to combat the world’s
leading cause of death. Findings from the 2015 he Global
Burden of Diseases, Injuries, and Risk Factors Study1
indicate that, in Denmark, approximately 44% of deaths
due to cardiovascular disease are associated with dietary
risk factors. Globally, this proportion is closer to 56%,
with the primary dietary risk factor associated with the
development of cardiovascular disease being a low intake
of fruits.2
One hypothesis to explain the cardioprotective effects
of fruits and many vegetables is that these benefits are
partly due to flavonoids, a group of bioactive compounds.3
Flavonoids are also found in other plant-based foods and
beverages such as tea, cocoa, and red wine and are
www.thelancet.com/planetary-health Vol 3 November 2019

categorised into subclasses on the basis of their chemical
structure.4 These structural variations yield differences in
bioavailability and biological activity, making the
individual assessment of the effects of these subclasses
particularly informative.5 However, flavonoid compounds
from different subclasses are catabolised by the gut
microbiome into smaller phenolic and aromatic acids
that are common to several subclasses.6 Therefore,
assessing total flavonoid intake is also of value.
Small-scale, short-term intervention studies have
explored the effects of flavonoids on validated measures of
vascular health. These studies have shown that flavonoidrich foods and specific flavonoid compounds can have a
positive effect on surrogate markers of cardiovascular
health such as blood pressure, vascular function, arterial
stiffness, blood lipids, and inflam
mation.7 Evidence
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Research in context
Evidence before this study
We searched Google Scholar and PubMed for studies in any
language published up to and including Jan 31, 2019 (with no
earliest date specified), analysing the association between
flavonoid intake and cardiovascular disease. We used the search
terms “flavonoid”, “polyphenol”, “cardiovascular disease”, “heart
disease”, and “stroke”. In a 2015 meta-analysis of 15 prospective
cohort studies, individuals with the highest flavonoid intakes
had a 15% lower relative risk of coronary heart disease compared
with that of individuals with the lowest intakes. Although
evidence suggests that flavonoids afford protection against
atherosclerosis, to our knowledge, no studies have investigated
the association between flavonoid intake and all cardiovascular
diseases with an atherosclerotic cause. Additionally, although
hypothesised, previous studies have been underpowered to
detect differing associations in at-risk subpopulations.
Added value of this study
Our study provides evidence of non-linear associations
between total flavonoid intake and atherosclerotic

See Online for appendix

suggests that flavonoids might ameliorate the initiation
and progression of atherosclerosis, the leading cause of
cardio
vascular disease, through regulation of inflam
mation and redox processes.8 Large long-term epide
miological studies are now needed to examine associations
between flavonoid intake and atherosclerotic cardio
vascular disease, particularly in subpopulations prone to
atherosclerosis.9
Therefore, the primary aim of our study was to
investigate the association of total flavonoid intake and
intake by flavonoid subclass and of major flavonoid
compounds with incident atherosclerotic cardiovascular
disease in the Danish Diet, Cancer, and Health cohort.
Secondary aims were to assess whether these associ
ations differed by sex, smoking status, alcohol consump
tion, body-mass index (BMI), and presence of prevalent
diabetes.

Methods

Study design and population
For our prospective cohort study, we used the Danish
Diet, Cancer, and Health study, an associated cohort of
the European Prospective Investigation into Nutrition
and Cancer, which recruited residents of the greater
areas of Copenhagen and Aarhus.10 Eligible participants
for this study were aged 50–65 years and had completed a
food-frequency questionnaire at baseline in the Danish
Diet, Cancer, and Health study. Using the Danish civil
registration system, we linked participants to nationwide
registers on the individual level. The following databases
were cross-linked to the cohort: the Civil Registration
System, the Integrated Database for Labor Market
Research, and the Danish National Patient Register
e451

cardiovascular disease, which plateau at intakes of
approximately 1000 mg per day. To our knowledge, this is the
first study to show that for smokers and consumers of high
quantities of alcohol, the association between flavonoid intake
and atherosclerotic cardiovascular disease was stronger and
additional benefit was seen for higher intakes compared with
that for non-smokers and individuals who consumed
low-to-moderate amounts of alcohol. Furthermore, this is the
first study to suggest that cardiovascular protective effects of
flavonoids occur primarily in the peripheral arteries.
Implications of all the available evidence
These findings highlight a potential strategy to improve
population health with dietary recommendations ensuring the
adequate consumption of flavonoid-rich foods. Our findings
suggest that flavonoids might have an even more crucial role in
the prevention of atherosclerotic cardiovascular disease in
high-risk populations.

(DNPR). The DNPR holds information on date of
hospital admissions in Denmark since 1978 and date of
discharge with one primary diagnosis and one or more
secondary diagnoses defined by the International
Classification of Diseases (ICD), the 8th revision (ICD-8)
until 1993 and the 10th revision (ICD-10) from
1994 onwards (appendix p 1).11 Participants were excluded
if they had any prevalent atherosclerotic cardiovascular
disease, which included self-reported myocardial infar
ction, previous diagnosis of ischaemic heart disease, selfreported ischaemic stroke, previous diagnosis of
ischaemic stroke, or previous diag
nosis of peripheral
artery disease. Furthermore, participants were excluded
if they had missing covariates, were extreme outliers
(appendix p 7), or had implaus
ible energy intakes
(<2092 kJ per day [<500 kcal per day] or >20 920 kJ per
day [>5000 kcal per day]).
In Denmark, register studies do not require approval
from an ethics committee. This study was approved by
the Danish Data Protection Agency.

Procedures
Exposures in our study were intakes of total flavonoids,
and flavonoid subclasses and individual flavonoid
compounds with mean intakes greater than 5 mg per
day. These intakes were estimated from dietary data,
collected at baseline by use of a validated 192-item foodfrequency questionnaire mailed out to participants
before their visit to one of the two study centres.12
Full details of the Phenol-Explorer calculations have
been published previously.13,14 Phenol-Explorer is a
comprehensive database on the flavonoid and, more
broadly, the polyphenol content of more than 400 foods.
www.thelancet.com/planetary-health Vol 3 November 2019
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Total population
(n=53 552)

Total flavonoid intake
Quintile 1 (n=10 711)

Total flavonoid intake (mg per day)

499 (290–808)

175 (129–215)

Quintile 2 (n=10 710)
323 (290–360)

Quintile 3 (n=10 710)
498 (445–552)

Quintile 4 (n=10 710)
730 (663–808)

Quintile 5 (n=10 711)
1205 (1028–1437)

Sex
Men

24 952 (46·6%)

6069 (56·7%)

5392 (50·3%)

4999 (46·7%)

4644 (43·4%)

3848 (35·9%)

Women

28 600 (53·4%)

4642 (43·3%)

5318 (49·7%)

5711 (53·3%)

6066 (56·6%)

6863 (64·1%)

Age (years)

56 (52–60)

55 (52–60)

56 (52–60)

56 (52–60)

56 (52–60)

55 (52–59)

BMI (kg/m²)

25·5 (23·2–28·1)

26·1 (23·7–28·8)

25·8 (23·6–28·4)

25·5 (23·3–28·2)

25·3 (23·1–27·8)

24·8 (22·7–27·3)

MET score

56·5 (37·0–84·8)

51·0 (32·5–78·0)

55·5 (36·5–84·0)

57·3 (38·5–84·7)

58·5 (38·8–87·0)

60·0 (40·0–88·5)

Smoking status
Never

19 258 (36·0%)

2724 (25·4%)

3684 (34·4%)

3922 (36·6%)

4322 (40·4%)

4606 (43·0%)

Former

15 205 (28·4%)

2524 (23·6%)

2867 (26·8%)

3059 (28·6%)

3405 (31·8%)

3350 (31·3%)

Current

19 089 (35·6%)

5463 (51·0%)

4159 (38·8%)

3729 (34·8%)

2983 (27·9%)

2755 (25·7%)

Education (years)
≤7

17 293 (32·3%)

4832 (45·1%)

3990 (37·3%)

3365 (31·4%)

2838 (26·5%)

2268 (21·2%)

8–10

24 836 (46·4%)

4718 (44·0%)

5083 (47·5%)

5158 (48·2%)

5083 (47·5%)

4794 (44·8%)

≥11

11 400 (21·3%)

1156 (10·8%)

1634 (15·3%)

2183 (20·4%)

2784 (26·0%)

3643 (34·0%)

Mean household income (DKK per year)
≤394 700

13 044 (24·4%)

3122 (29·1%)

2569 (24·0%)

2550 (23·8%)

2422 (22·6%)

2381 (22·2%)

394 701–570 930

13 289 (24·8%)

3095 (28·9%)

2848 (26·6%)

2577 (24·1%)

2467 (23·0%)

2302 (21·5%)
2464 (23·0%)

570 931–758 297

13 500 (25·2%)

2827 (26·4%)

2924 (27·3%)

2765 (25·8%)

2520 (23·5%)

>758 297

13 719 (25·6%)

1667 (15·6%)

2369 (22·1%)

2818 (26·3%)

3301 (30·8%)

3564 (33·3%)

Hypertensive

8201 (15·3%)

1597 (14·9%)

1694 (15·8%)

1662 (15·5%)

1642 (15·3%)

1606 (15·0%)

Hypercholesterolaemic

3397 (6·3%)

696 (6·5%)

676 (6·3%)

703 (6·6%)

707 (6·6%)

615 (5·7%)

1000 (1·9%)

240 (2·2%)

189 (1·8%)

202 (1·9%)

180 (1·7%)

189 (1·8%)

91 (0·2%)

16 (0·1%)

23 (0·2%)

18 (0·2%)

17 (0·2%)

17 (0·2%)

209 (0·4%)

37 (0·3%)

45 (0·4%)

43 (0·4%)

36 (0·3%)

48 (0·4%)

Comorbidities
Diabetes
Heart failure
Atrial fibrillation
COPD

751 (1·4%)

190 (1·8%)

160 (1·5%)

142 (1·3%)

139 (1·3%)

120 (1·1%)

CKD

178 (0·3%)

35 (0·3%)

28 (0·3%)

39 (0·4%)

40 (0·4%)

36 (0·3%)

Cancer

227 (0·4%)

48 (0·4%)

40 (0·4%)

55 (0·5%)

32 (0·3%)

52 (0·5%)

Medication use
Insulin
Antihypertensive
Statin

331 (0·6%)

70 (0·7%)

57 (0·5%)

71 (0·7%)

69 (0·6%)

64 (0·6%)

6122 (11·4%)

1181 (11·0%)

1287 (12·0%)

1242 (11·6%)

1212 (11·3%)

1200 (11·2%)

624 (1·2%)

133 (1·2%)

138 (1·3%)

129 (1·2%)

122 (1·1%)

102 (1·0%)
3650 (34·1%)

HRT
15 553 (29·0%)

2560 (23·9%)

2976 (27·8%)

3163 (29·5%)

3204 (29·9%)

Current

8610 (16·1%)

1283 (12·0%)

1513 (14·1%)

1664 (15·5%)

1948 (18·2%)

2202 (20·6%)

Former

4406 (8·2%)

790 (7·4%)

825 (7·7%)

875 (8·2%)

910 (8·5%)

1006 (9·4%)

Never

NSAID

17 081 (31·9%)

Aspirin

6484 (12·1%)

1233 (11·5%)

3268 (30·5%)

1254 (11·7%)

3312 (30·9%)

1318 (12·3%)

3444 (32·2%)

1280 (12·0%)

3433 (32·1%)

1399 (13·1%)

3624 (33·8%)

9498 (7852–11 365)

8600 (7025–10 396)

9249 (7715–11 009)

9742 (8126–11 581)

9922 (8315–11 807)

9920 (8255–11 875)

Dietary characteristics (g per day)
Energy (kj)
Total fish intake

38 (25–55)

33 (22–48)

38 (25–54)

39 (27–57)

41 (28–59)

Red meat intake

78 (56–107)

80 (57–108)

81 (59–109)

80 (58–110)

78 (56–107)

72 (52–99)

Processed meat intake

24 (14–40)

28 (17–45)

26 (15–42)

25 (14–40)

23 (14–37)

20 (11–34)

Dietary fibre intake

20 (16–25)

17 (13–20)

19 (16–23)

21 (17–25)

Fruit intake

172 (95–282)

88 (45–142)

162 (98–239)

193 (114–301)

225 (140–360)

240 (141–390)

Vegetable intake

162 (105–231)

115 (72–171)

150 (100–212)

168 (114–236)

185 (127–254)

196 (136–272)

Alcohol intake

13 (6–31)

11 (3–23)

13 (6–25)

15 (6–33)

22 (18–27)

39 (27–56)

14 (7–32)

23 (19–29)

13 (6–32)

Data are median (IQR) or n (%), unless otherwise specified. BMI=body-mass index. MET=metabolic equivalent. DKK=Danish Krone. COPD=common obstructive pulmonary disease. CKD=chronic kidney disease.
HRT=hormone replacement therapy. NSAID=non-steroidal anti-inflammatory drug.

Table 1: Baseline characteristics
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1·0

disease, chronic obstructive pulmonary disease, heart
failure, atrial fibrillation, and cancers. For hypertension
and diabetes, only self-reported data were used because
of the low validity of ICD codes in DNPR.16

0·9

Outcomes

Total number of hospital admissions

Hazard ratio (95% CI)

1·1

0·8

Hazard ratio (95% CI)

Hospital admission by disease subtype
IHD
PAD
Stroke

1·1
1·0
0·9
0·8
0·7
500

1000

1500

2000

Total flavonoid intake (mg per day)

Figure 1: Association between total flavonoid intake and hospital admissions
for atherosclerotic cardiovascular disease
Cubic spline curves describe the association between total flavonoid intake
(mg per day) and hospital admissions for both total atherosclerotic cardiovascular
disease and disease subtypes. Hazard ratios are based on Cox proportional hazards
models adjusted for age, sex, body-mass index, smoking status, socioeconomic
status (income), physical activity, and alcohol intake (model 2), and are
comparing the specific level of flavonoid intake (horizontal axis) with the median
intake for participants in the lowest intake quintile (175 mg per day).
IHD=ischaemic heart disease. PAD=peripheral artery disease.

Significant correlations have been found between 24-h
urine concentrations of 12 flavonoids and intake of their
main food sources in 475 participants of the EPIC study.15
In our study, we estimated the intakes of 219 different
flavonoids. These were grouped into nine classes
according to their chemical structure (flavonols, flavones,
flavanols [flavanol monomers and flavanol oligomers
and polymers], flavanones, isoflavones, anthocyanins,
chalcones, dihydrochalcones, and dihydro
flavonols)
by summing the intakes of each individual flavonoid
compound within their respective flavonoid class. We
calculated total flavonoid intake by summing each of the
flavonoid compounds.
We obtained information on sex, age, education,
smoking habits, alcohol consumption, and daily activity
from self-administered questionnaires completed by
participants at Danish Diet, Cancer, and Health study
enrolment. Dietary data were obtained from the semiquantitative food frequency questionnaire. Anthro
pometric measures and total blood cholesterol were
taken at the Danish Diet, Cancer, and Health study
centres. We defined average annual income as household
income after taxation and interest, for the value of the
Danish currency in 2015, and we used the value over
5 years as a proxy for socioeconomic status. We used
ICD-8 and ICD-10 codes for diagnosis of chronic kidney
e453

The primary outcome was a combined endpoint of
first-time hospital admission for atherosclerotic cardio
vascular disease. Atherosclerotic cardiovascular disease
was defined as hospital admission with a primary or
secondary diagnosis code for ischaemic heart disease,
ischaemic stroke, or peripheral artery disease. Secondary
outcomes were discrete hospital admissions for
ischaemic heart disease, ischaemic stroke, and peripheral
artery disease. These ICD codes have previously been
validated in the DNPR.16 Diagnoses of unstable angina or
transient ischaemic attack were not included because
these do not have validity and specificity in the DNPR.
To verify the registry-based outcomes, we re-examined
associations using only medically reviewed and validated
cases (appendix p 1).

Statistical analysis
Participants were followed up for a maximum of
23 years from the date of enrolment until death from
any cause, emigration, hospital admission for
atherosclerotic cardiovascular disease (first hospital
admission for the combined endpoint), or end of followup (August, 2017), whichever came first. We computed
Nelson-Aalen plots of cumulative incidence for
atherosclerotic cardiovascular disease with a competing
risk of death and by quintile of total flavonoid intake.
We used restricted cubic splines with four knots (located
at the fifth, 35th, 65th, and 95th percentiles) to
investigate non-linear relationships between flavonoid
intakes and all outcomes, with hazard ratios (HRs)
derived from Cox proportional hazards models. We
plotted HRs with 95% CIs for each unit of the exposure
using the median intake in quintile 1 as the reference.
Individuals with intakes greater than 4 SD above the
mean were excluded from the spline analysis. The test
of non-linearity used analysis of variance to compare the
model only with the linear term to the model that
included both linear and non-linear terms. We obtained
HRs and 95% CIs for the median intakes in each
quintile of the exposure variables from the splines. Cox
proportional hazards assumptions were tested using
log-log plots of the survival function versus time and
assessed for parallel appearance, with no violation
found. Because our aim was to obtain relative estimates
sored rather
for risk factors, all deaths were cen
than treated as a competing risk. We used six models
of adjustment: minimally adjusted (model 1), multi
variable-adjusted (model 2), multivariable-adjusted
including energy (model 3), multivariable-adjusted inc
luding covariates on the causal pathway (model 4),
multivariable-adjusted including potential dietary
www.thelancet.com/planetary-health Vol 3 November 2019
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However, energy intake was added to model 2 in a
sensitivity analysis (model 3). Analyses were stratified
by sex, BMI, baseline diabetes status, smoking status,
and alcohol intake to test for potential effect
modification. When stratifying by alcohol intake, we
excluded all participants with an alcohol intake of
zero (1180 participants) and when stratifying by BMI,
we excluded those with a BMI lower than 18·5
(426 participants), because these were not our subgroups

confounders (model 5), and multivariable-adjusted
including potential dietary confounders that are also a
source of flavonoids (model 6; appendix p 1). Covariates
were chosen a priori according to the best of our
knowledge of potential confounders of flavonoid intake
and cardio
vascular disease. We assumed absolute
flavonoid intake to be more relevant than energyadjusted values; therefore we did not include total
energy intake as a covariate in the main models.
Quintile 1 (n=10 711) Quintile 2 (n=10 710)

Quintile 3 (n=10 710)

Quintile 4 (n=10 710)

Quintile 5 (n=10 711)

2199

1749

1573

1408

Total flavonoids
Number of events
Intake (mg per day)*

175 (6–253)

1844
323 (253–397)

498 (397–605)

730 (605–912)

1205 (912–3552)

HR (95% CI)
Model 1

1 (ref)

0·84 (0·81–0·87)

0·74 (0·71–0·78)

0·70 (0·66–0·73)

0·66 (0·63–0·70)

Model 2

1 (ref)

0·94 (0·90–0·97)

0·89 (0·85–0·94)

0·87 (0·82–0·92)

0·85 (0·81–0·91)

Model 5

1 (ref)

0·95 (0·91–0·99)

0·91 (0·87–0·96)

0·90 (0·85–0·95)

0·89 (0·84–0·95)

Flavonols
Number of events

2257

Intake (mg per day)*

15 (0–21)

2581
26 (21–32)

2285
39 (32–50)

2194
66 (50–83)

2133
116 (83–251)

HR (95% CI)
Model 1

1 (ref)

0·83 (0·80–0·86)

0·73 (0·69–0·76)

0·67 (0·63–0·70)

0·65 (0·61–0·69)

Model 2

1 (ref)

0·92 (0·88–0·95)

0·86 (0·82–0·91)

0·85 (0·80–0·89)

0·84 (0·79–0·89)

Model 5

1 (ref)

0·92 (0·89–0·96)

0·88 (0·83–0·93)

0·87 (0·82–0·92)

0·87 (0·82–0·92)

Flavanol monomers
Number of events

2279

Intake (mg per day)*

14 (0–21)

1826
30 (21–46)

1722
68 (46–116)

1546
261 (116–282)

1400
474 (282–916)

HR (95% CI)
Model 1

1 (ref)

0·90 (0·88–0·92)

0·75 (0·71–0·80)

0·68 (0·64–0·72)

0·68 (0·64–0·72)

Model 2

1 (ref)

0·95 (0·93–0·97)

0·88 (0·83–0·93)

0·86 (0·82–0·92)

0·87 (0·82–0·92)

Model 5

1 (ref)

0·96 (0·94–0·98)

0·90 (0·85–0·95)

0·89 (0·84–0·94)

0·90 (0·84–0·95)

Flavanol oligo+polymers
Number of events
Intake (mg per day)*

2192
93 (0–137)

1934
180 (137–218)

1631
257 (218–304)

1578
361 (304–435)

1438
538 (435–2254)

HR (95% CI)
Model 1

1 (ref)

0·82 (0·78–0·85)

0·73 (0·70–0·77)

0·68 (0·64–0·71)

0·65 (0·62–0·69)

Model 2

1 (ref)

0·93 (0·89–0·97)

0·87 (0·83–0·92)

0·83 (0·78–0·88)

0·82 (0·78–0·87)

Model 5

1 (ref)

0·94 (0·90–0·98)

0·89 (0·85–0·94)

0·86 (0·81–0·90)

0·86 (0·81–0·91)

Anthocyanins
Number of events
Intake (mg per day)*

2043
5 (0–9)

1660
13 (9–17)

1597
20 (17–24)

1735
35 (24–53)

1738
70 (53–397)

HR (95% CI)
Model 1

1 (ref)

0·77 (0·73–0·80)

0·71 (0·67–0·75)

0·75 (0·71–0·79)

0·83 (0·78–0·88)

Model 2

1 (ref)

0·91 (0·87–0·96)

0·89 (0·84–0·95)

0·94 (0·88–0·99)

0·98 (0·92–1·05)

Model 5

1 (ref)

0·92 (0·88–0·97)

0·91 (0·85–0·97)

0·96 (0·90–1·02)

1·01 (0·94–1·07)

Flavanones
Number of events
Intake (mg per day)*

1939

1734

1761
18 (13–26)

1591
32 (26–50)

1748

3 (0–6)

9 (6–13)

70 (50–364)

Model 1

1 (ref)

0·92 (0·88–0·96)

0·85 (0·80–0·91)

0·83 (0·79–0·88)

0·86 (0·81–0·91)

Model 2

1 (ref)

0·98 (0·94–1·02)

0·96 (0·90–1·02)

0·93 (0·88–0·99)

0·95 (0·90–1·01)

Model 5

1 (ref)

0·99 (0·95–1·03)

0·97 (0·91–1·03)

0·95 (0·89–1·00)

HR (95% CI)

0·96 (0·91–1·02)
(Table 2 continues on next page)
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Quintile 1 (n=10 711) Quintile 2 (n=10 710)

Quintile 3 (n=10 710)

Quintile 4 (n=10 710)

Quintile 5 (n=10 711)

1672

1644

1707

(Continued from previous page)
Flavones
Number of events

1941

Intake (mg per day)*

1809

2 (0–3)

4 (3–5)

5 (5–6)

7 (6–9)

11 (9–51)

Model 1

1 (ref)

0·84 (0·79–0·88)

0·80 (0·75–0·84)

0·77 (0·73–0·81)

0·79 (0·75–0·84)

Model 2

1 (ref)

0·93 (0·88–0·98)

0·91 (0·86–0·96)

0·89 (0·84–0·94)

0·90 (0·85–0·96)

Model 5

1 (ref)

0·94 (0·89–0·99)

0·93 (0·87–0·98)

0·91 (0·86–0·97)

0·94 (0·88–1·00)

HR (95% CI)

Hazard ratios (HR; 95% CI) for hospital admissions for atherosclerotic cardiovascular disease during 23 years of follow-up, obtained from restricted cubic splines based on Cox
proportional hazards models. Model 1 adjusted for age and sex; model 2 adjusted for age, sex, body-mass index, smoking status, physical activity, alcohol intake, and social
economic status (income); model 5 adjusted for all covariates in model 2 plus intakes of fish, red meat, processed food, polyunsaturated fatty acids, monounsaturated fatty
acids, and saturated fatty acids. *Median (range).

1·2

Hazard ratio (95% CI)

Hazard ratio (95% CI)

Table 2: Hospital admissions for atherosclerotic cardiovascular disease by quintiles of flavonoid intake

1·1
1·0
0·9
0·8
0·7

0

50

100

150

the report. FD, NPB, and GG had full access to all the
data in the study. All authors had final responsibility for
the decision to submit for publication.

1·1
1·0
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1·2
1·1
1·0
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Anthocyanidin intake (mg per day)
Hazard ratio (95% CI)

Hazard ratio (95% CI)

1·4

0
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1·2

Flavanol oligo+polymers intake (mg per day)

0·8
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Flavanol monomer intake (mg per day)
Hazard ratio (95% CI)
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Total flavonol intake (mg per day)

250

1·4
1·2
1·1
1·0
0·9
0·8

0

Flavanone intake (mg per day)

5
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15

20

Flavone intake (mg per day)

Figure 2: Association between flavonoid subclass intakes (mg per day) and total hospital admissions for
atherosclerotic cardiovascular disease
Hazard ratios are based on Cox proportional hazards models adjusted for age, sex, body-mass index, smoking status,
social economic status (income), physical activity, and alcohol intake (model 2), and are comparing the specific level
of flavonoid intake (horizontal axis) with the median intake for participants in the lowest intake quintile.

of interest. We chose stratification cutoff points of 20 g
pure alcohol per day (two standard drinks) and a BMI of
30 kg/m², because the risk of mortality is higher beyond
these levels.17 We did analyses using STATA/IC, version
14.2, and R statistics. Statistical significance was set at
p≤0·05 (two-tailed) for all tests.

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
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Between Nov 24, 1993, and May 28, 1997, the Danish
Diet,
Cancer,
and
Health
study
recruited
57 053 participants. Of these, 56 468 completed a foodfrequency questionnaire at baseline. 2916 participants
did not meet the inclusion criteria, resulting in a study
population of 53 552 participants (appendix p 2).
Our study cohort had a median age of 56 years
(IQR 52–60) at entry and a median follow-up of 21 years
(15–22). During a total of 939 031 person-years of followup, 8773 individuals were admitted to hospital for any
atherosclerotic cardiovascular disease, 5323 for ischaemic
heart disease, 2920 for ischaemic stroke, and 1867 for
peripheral artery disease. Furthermore, 9522 participants
died from any cause without having been admitted to
hospital for an atherosclerotic cardiovascular disease.
The cumulative incidence of hospital admissions for
atherosclerotic cardiovascular disease and death without
admission for atherosclerotic cardiovascular disease are
shown in the appendix (p 3).
Participants in the highest quintile of flavonoid intake
were more likely to be women and tended to have a lower
BMI; be more physically active; have never smoked; have
a higher education degree; have a higher income; eat
more fish, fibre, vegetables, and fruit; and eat less red
and processed meat than participants in the lowest
quintile of flavonoid intake (table 1).
Cumulative incidences of atherosclerotic cardiovascular
disease, ischaemic heart disease, ischaemic stroke, and
peripheral artery disease for each quintile of total
flavonoid intake are shown in the appendix (p 3). The
inverse association between total flavonoid intake and
sclerotic cardiovascular disease was nontotal athero
linear (p<0·001), and the restricted cubic splines showed
a threshold of association at approximately 1000 mg per
day (figure 1). Compared with a total flavonoid intake of
www.thelancet.com/planetary-health Vol 3 November 2019
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Hazard ratio (95% CI)
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Hazard ratio (95% CI)

175 mg per day (median intake in quintile 1), an intake of
1000 mg per day was associated with a 14% lower risk of
atherosclerotic cardiovascular disease (HR 0·86, 95% CI
0·81–0·91). For atherosclerotic cardiovascular disease
subtypes, a total flavonoid intake of 1000 mg per day was
associated with a 9% lower risk of ischaemic heart
disease (0·91, 0·85–0·98), a non-significant 9% lower
risk of ischaemic stroke (0·91, 0·82–1·01), and a
32% lower risk of peripheral artery disease (0·68,
0·60–0·78) compared with a 175 mg per day intake
(model 2). For all flavonoid subclasses, after multi
variable adjustments (models 2 and 3), participants in
quintiles 2–5 had a lower risk of atherosclerotic
cardiovascular disease than that of participants in
quintile 1 (table 2). HRs for alternative models of
adjustment (models 4 and 6) did not differ substantively
from HRs from model 2 (appendix p 4). We observed
thresholds of benefit at varying levels of intake for each
flavonoid subclass (figure 2).
Intakes of kaempferol, quercetin, epicatechin, procy
anidin dimers, and apigenin greater than those in
quintile 1 were associated with a significantly lower risk
of hospital admissions for atherosclerotic cardiovascular
disease after adjustment for potential lifestyle (model 2)
and dietary confounders (model 5), with no further
differences in HRs observed beyond quintile 4 (figure 3,
appendix pp 5–6). The observed association was more
linear for malvidin and procyanidin trimers than for
other compounds. The HRs were 0·76 (95% CI
0·70–0·83) for malvidin and 0·79 (0·74–0·84) for
procyanidin trimers in quintile 5 versus quintile 1 after
adjustment for potential lifestyle confounders (model 2).
The association between flavonoid intake and athero
sclerotic cardiovascular disease differed according to
smoking status, alcohol intake, and BMI, but not by
prevalence of diabetes or by sex for intakes lower than
1000 mg per day.
Because we observed no difference in the association
between flavonoid intake and hospital admissions for
atherosclerotic cardiovascular disease for never smokers
compared with that for former smokers, these subgroups
were combined (data not shown). The inverse associ
ation between total flavonoid intake and atherosclerotic
cardiovascular disease was stronger in smokers than
in non-smokers and stronger in participants who
consumed more than 20 g per day of alcohol than in those
who consumed 20 g per day or less of alcohol (figure 4). A
total flavonoid intake of 1000 mg per day was associated
with a 22% lower risk of atherosclerotic cardiovascular
disease in smokers (HR 0·78, 95% CI 0·72–0·85), a
non-significant 5% lower risk in non-smokers (0·95,
0·87–1·03), a 21% lower risk in high alcohol consumers
(0·79, 0·71–0·87), and an 11% lower risk in low-tomoderate alcohol consumers (0·89, 0·82–0·95; model 2).
Comparing participants in quintile 5 with those in
quintile 1 of total flavonoid intake, the HRs for hospital
admissions for atherosclerotic cardiovascular disease

Hazard ratio (95% CI)
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1·3
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1·1
1·0
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0·8
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Apigenin intake (mg per day)

Figure 3: Association between major flavonoid compound intakes (mg per day) and total hospital admissions
for atherosclerotic cardiovascular disease
Hazard ratios are based on Cox proportional hazards models adjusted for age, sex, body-mass index, smoking status,
social economic status (income), physical activity, and alcohol intake (model 2), and are comparing the specific level
of flavonoid intake (horizontal axis) with the median intake for participants in the lowest intake quintile.

lowered with increasing smoking intensity (pack-years)
and were lowest for participants who consumed 20–40 g
per day of alcohol (appendix p 6). We observed a lower
risk of atherosclerotic cardiovascular disease associated
with higher flavonoid intake in participants with normal
weight and overweight (BMI 18·5–30), but not in those
who were obese (BMI >30; figure 4, appendix p 6). A total
flavonoid intake of 1000 mg per day was associated with a
20% lower risk of atherosclerotic cardiovascular disease
in partici
pants with BMI 18·5–30 (HR 0·80, 95% CI
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Figure 4: Stratified, multivariable-adjusted associations between total flavonoid intake and total hospital
admissions for atherosclerotic cardiovascular disease
Multivariable-adjusted associations are stratified by baseline smoking status, alcohol intake, BMI, and sex.
Hazard ratios are based on Cox proportional hazards models and are comparing the specific level of flavonoid
intake (horizontal axis) with the median intake for participants in the lowest intake quintile (175 mg per day).
All analyses were standardised for age, sex, BMI, smoking status, social economic status (income), physical activity,
and alcohol intake (model 2), not including the stratification variable for each subgroup. BMI=body-mass index.

0·75–0·86) than an intake of 175 mg per day, but no lower
risk in participants with a BMI higher than 30 (HR 0·99,
0·87–1·14). A difference in association between men
and women was apparent only for intakes greater than
1000 mg per day, in which 95% CIs also widened
substantially.
Using only validated cases, and after excluding a
further seven participants who had a diagnosis
of validated atherosclerotic cardiovascular disease
(n=53 545), 3479 participants were admitted to hospital
for any atherosclerotic cardiovascular disease, 2505 were
admitted for myocardial infarction, 923 for ischaemic
stroke, and 818 for peripheral artery disease. Compared
with a total flavonoid intake of 175 mg per day (median
intake in quintile 1), an intake of 1000 mg per day was
associated with a 17% lower risk of atherosclerotic
cardiovascular disease (HR 0·83, 95% CI 0·76–0·91). For
atherosclerotic cardiovascular disease subtypes, a total
flavonoid intake of 1000 mg per day, compared with the
median intake in quintile 1, was associated with a nonsignificant 9% lower risk of myocardial infarction (0·91,
0·82–1·02), an 18% lower risk of ischaemic stroke (0·82,
0·68–0·98), and a 35% lower risk of peripheral artery
disease (0·65, 0·53–0·79; appendix p 7).

Discussion
Diet is a primary modifiable risk factor for cardiovascular
disease.2 Therefore, dietary changes have great potential
to affect cardiovascular disease incidence, especially in
populations at high risk. In this prospective cohort study
of 53 552 Danish people without atherosclerotic cardio
vascular disease at recruitment, we found that a moderate
e457

intake of flavonoids was inversely associated with
incident hospital admissions for atherosclerotic cardio
vascular disease, with no additional benefits seen for
intakes greater than 1000 mg per day. This inverse
association was strongest in subpopulations prone to
atherosclerosis including smokers and individuals who
consumed high quantities of alcohol.
Flavonoid intake in Denmark is similar to intakes
reported for other European countries and generally
lower than intakes reported for the UK, because of a
lower average consumption of tea.13 In the past few
years, studies assessing the relationship between
flavonoid intake and cardiovascular disease have
focused primarily on mortality from any cardiovascular
disease18 or coronary heart disease and ischaemic stroke,
both individually and combined.19,20 A 2017 meta-analysis
found that total flavonoid intake was marginally, but not
significantly, associated with a lower risk of cardio
vascular disease mortality (relative risk 0·85, 95% CI
0·70–1·03) for the highest versus lowest category of
total flavonoid intake;18 similar risk estimates have been
reported in other meta-analyses.21,22 Indeed, our previous
study in the Danish Diet Cancer, and Health cohort
showed that participants in the highest quintile of
flavonoid intake had a 15% lower risk of cardiovascular
disease mortality (HR 0·85, 95% CI 0·78–0·93) than
that of participants in the first quintile.23 Although a
trend for a reduced risk of cardiovascular disease
with higher levels of flavonoid intake exists, this is
generally non-significant after adjusting for potential
confounders.18 In this study, we used hospital admission
for ischaemic heart disease, ischaemic stroke, and
peripheral artery disease as markers of atherosclerotic
and thromboembolic cardiovascular disease rather than
an unselective array of cardiovascular disease diagnoses.
These events were our chosen outcomes of interest
because in-vivo evidence suggests that flavonoids might
impede the initiation and progression of atherosclerosis
by restoring endothelial homoeostasis and attenuating
inflammation.7 In our study, total flavonoid intake was
significantly associated with less hospital admissions
for atherosclerotic cardiovascular disease after adjust
ment for potential lifestyle and dietary confounders.
This result might be due to our use of hospital
admissions rather than mortality, allowing us to include
peripheral artery disease, which is an underlying risk
factor for cardiovascular disease mortality and a marker
of widespread atherosclerosis, but is rarely fatal in
itself.24 To our knowledge, one other observational study
(n=1658) has looked at combined cardiovascular disease
incidence, including peripheral artery disease, and
reported an inverse association with total flavonoid
intake when comparing the highest tertile with the
lowest (HR 0·46, 95% CI 0·28–0·75).25 In our study, the
inverse association between total flavonoid and athero
sclerotic cardiovascular disease plateaued at intakes of
approximately 1000 mg per day. Two cups of black tea,
www.thelancet.com/planetary-health Vol 3 November 2019
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100 g of blueberries, one apple, one glass of red wine,
100 g of black beans, and 100 g of dark chocolate
would provide more than 1000 mg of flavonoids.4
Evidence exists that flavonoid bioactivity does not follow
a classic linear dose–response association.20 However,
the threshold might differ in specific subpopulations at
elevated cardiovascular disease risk, such as smokers
and individuals who consume high quantities of
alcohol.
Flavonoids have been reported to positively influence
cardiovascular disease by acting upon common crosstalking proteins that control the anti-inflammatory Nrf2
pathway and the pro-inflammatory NF-Kβ pathway.7
Additionally, after metabolism, flavonoid conjugates in
the circulatory system can act on both endothelial cells
and underlying smooth muscle cells, regulating vascular
health7 We provide hypothesis-stimulating evidence that
the inverse associations observed for flavonoid intake
were strongest for peripheral artery disease, followed by
ischaemic stroke and ischaemic heart disease. This might
be due to the underlying pathology of these diseases
and the mechanisms by which flavonoids exert their
cardiovascular protective effects, which our results
suggest are primarily in the peripheral arteries and
should be investigated further.
Results from our study indicate that the inverse
association between flavonoid intake and atherosclerotic
cardiovascular disease was stronger in current smokers
and individuals who consume high quantities of alcohol,
two populations at a higher risk of atherosclerosis and
clinical atherosclerotic cardiovascular disease than those
who do not smoke or drink or do so in low quantities.
Cigarette smoking is an important risk factor for
atherosclerosis and peripheral artery disease.26 In a
randomised controlled trial done in healthy smokers,
supplementation with flavonoid-rich grape juice restored
vascular function and decreased smoking-induced
inflammatory and fibrinolytic biomarkers.27 Taken
together, these findings provide evidence that flavonoidrich foods might mitigate the risk of athero
sclerotic
cardiovascular disease in smokers. The finding that the
inverse association was stronger in individuals with high
alcohol consumption is complex because red wine, a
dietary source of flavonoids, is linked with cardiovascular
health benefits.28 Drinking more than two standard
drinks per day has been consistently associated with an
elevated risk of cardiovascular disease by a plethora of
purported mechanisms, including an increase in blood
pressure, systemic atherosclerosis, and inflamma
tory
endothelial markers.29 The increasing evidence that
flavonoids might ameliorate the detrimental effects of
cigarette smoking and high alcohol consumption30,31 is
supported by our study.
The weaker inverse association observed between
flavonoid intake and atherosclerotic cardiovascular dis
ease in participants with obesity opposes our a-priori
hypothesis that flavonoids would be more protective in
www.thelancet.com/planetary-health Vol 3 November 2019

this subgroup, because this population is prone to higher
levels of atherosclerosis than those of individuals with
lower BMI. Although evidence exists that flavonoids
affect body composition,32 individuals with obesity have a
disparate gut microbial composition.33 This is important,
because the gut microbiome has a crucial role in
flavonoid metabolism and thus, in bioactivity,34 which
might explain the weak association in this subpopulation.
We should note the differing baseline hazards between
obese and non-obese subpopulations, indicating that
these findings require corroboration on an absolute
scale. With few people with diabetes at baseline, our
study was probably underpowered to detect a difference
in associ
ation between flavonoid intake and
atherosclerotic cardiovascular disease in this high-risk
population. Future research should assess if flavonoid
intake is associated with atherosclerotic cardiovascular
disease incidence in people with diabetes.
Our study has several strengths and some limitations.
The large adult population followed up for 23 years, with
a large number of events and almost no loss to follow-up,
allowed us to examine associations in subpopulations.
Our findings were supported, and even strengthened,
with the validated case analysis. Because of the nature of
the study, we were not able to infer causality or rule out
residual or unmeasured confounding; however, the
associations were not altered substantially by further
adjustments. We acknowledge the limitations of
common food-frequency questionnaires, particularly
that not all flavonoid-rich foods (eg, berries) were
included in the questionnaire. Because we only had
baseline data, we acknowledge that some of these
measures might have changed over the 23 years of
follow-up; however, this measurement error would have
most likely attenuated any associations. Furthermore,
because the Danish population is more homogeneous
than many other countries, further studies are warranted
to determine whether similar associations exist in
populations outside of this cohort.
In this Danish prospective cohort study, we observed
an inverse association between flavonoid intake of up to
1000 mg per day and hospital admissions for athero
sclerotic cardiovascular disease, after which we detected
no additional benefits. The strongest associations
observed were for peripheral artery disease and for
atherosclerotic cardio
vascular disease in smokers and
high alcohol consumers. These findings need to be
further explored and, if replicated, might provide a novel
means of mitigating athero
sclerotic cardiovascular
disease risk by ensuring an adequate consumption of
flavonoid-rich foods, particularly in subpopula
tions
prone to atherosclerosis.
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